New appointment helps local company go global

New appointment helps local company go global

Coventry-based Quantum Imaging Ltd, has appointed a business development director to develop its overseas distribution network and enable the company to grow globally.

Jag Buttoo joined the award winning company from GE Healthcare, where he held a number of senior sales positions in the UK, Ireland and the Middle East. He has more than 23 years’ experience in the medical industry, including five years of clinical experience as a qualified radiographer and 18 years in a commercial role working in a range of disciplines, such as cardiology.

In his role at Quantum Imaging, Mr Buttoo will establish the business’ overseas distribution network, focusing on Europe and the Middle East initially. He will also be responsible for the direct sales market in the UK and USA, looking to develop strong sales and marketing networks for the company’s first product, Vitalscan.

Vitalscan is set to revolutionise the detection of heart-related problems in acute medical settings. It is a portable medical device that can scan a patient with chest pain in less than five minutes, helping doctors to ‘rule out’ cardiac conditions, such as heart attacks. Vitalscan can be used in hospital accident and emergency departments or by a patient’s bedside placing it at the front-line of medical care.

Mr Buttoo said: “I have been looking for a role within an emerging technology company for some time and Quantum Imaging felt like a perfect fit. Its technology is going to be a game-changer for cardiology and helping to build the sales network from the ground up is a huge privilege. The company’s values and vision reflect my own and I am very excited to be part of such a forward-looking organisation.”

Mr Buttoo’s is the latest in a series of appointments at the organisation, spanning researchers and clinical managers, to business development specialists and technical engineers.

CEO of Quantum Imaging, Steve Parker, said: “With Vitalscan being taken forward for clinical trials later this year we are getting ever closer to commercialisation. We therefore need to be looking towards reaching out to global markets with this technology, maximising its potential to change lives for patients globally. Jag has the right mix of experience and enthusiasm to make this happen and we are very pleased to have him as part of the team.”

For further information, please contact:
Annabel John, Speed Communications
07771 916881
Annabel.john@speedcomms.com

Leander Clarke, Speed Communications
07985 238713
Leander.clarke@speedcomms.com